DK3093022T3 - Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma - Google Patents
Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma Download PDFInfo
- Publication number
- DK3093022T3 DK3093022T3 DK15001472T DK15001472T DK3093022T3 DK 3093022 T3 DK3093022 T3 DK 3093022T3 DK 15001472 T DK15001472 T DK 15001472T DK 15001472 T DK15001472 T DK 15001472T DK 3093022 T3 DK3093022 T3 DK 3093022T3
- Authority
- DK
- Denmark
- Prior art keywords
- astma
- gata
- inhibitors
- driven
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001472.8A EP3093022B1 (en) | 2015-05-15 | 2015-05-15 | Gata-3 inhibitors for use in the treatment of th2-driven asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3093022T3 true DK3093022T3 (da) | 2019-11-04 |
Family
ID=53274335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15001472T DK3093022T3 (da) | 2015-05-15 | 2015-05-15 | Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10487325B2 (da) |
| EP (1) | EP3093022B1 (da) |
| JP (1) | JP2018515611A (da) |
| KR (1) | KR20180004816A (da) |
| CN (2) | CN115137827A (da) |
| AU (1) | AU2016264772B2 (da) |
| BR (1) | BR112017024394A2 (da) |
| CA (1) | CA2985858C (da) |
| DK (1) | DK3093022T3 (da) |
| ES (1) | ES2753436T3 (da) |
| HU (1) | HUE046190T2 (da) |
| NZ (1) | NZ736807A (da) |
| PL (1) | PL3093022T3 (da) |
| PT (1) | PT3093022T (da) |
| RU (1) | RU2720988C2 (da) |
| SI (1) | SI3093022T1 (da) |
| WO (1) | WO2016184556A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3463388B1 (en) | 2016-05-24 | 2024-09-11 | Emory University | Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders |
| EP3501607A1 (de) * | 2017-12-22 | 2019-06-26 | Sterna Biologicals GmbH & Co. KG | Zusammensetzung zur behandlung eines an einer mit chronischen entzündungen einhergehenden atemwegserkrankung leidenden patienten sowie herstellungsverfahren und verwendung der zusammensetzung |
| EP3603617A1 (de) * | 2018-07-30 | 2020-02-05 | Sterna Biologicals GmbH & Co. KG | Aerosolerzeugungseinrichtung zur inhalativen verabreichung einer antisense-molekül-haltigen zusammensetzung |
| EP3805242A1 (en) | 2019-10-07 | 2021-04-14 | Sterna Biologicals GmbH & Co. KG | Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma |
| US11976282B2 (en) | 2020-06-23 | 2024-05-07 | Qatar University | GATA3 inhibitors for the promotion of subcutaneous fat deposition |
| CN112023062A (zh) * | 2020-09-18 | 2020-12-04 | 北京基因安科技有限公司 | 一个用可溶性IgE受体抑制过敏反应的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323344A (zh) | 1998-08-13 | 2001-11-21 | 庄臣及庄臣研究股份有限公司 | 治疗再狭窄的DNAzyme和方法 |
| AUPP810399A0 (en) | 1999-01-11 | 1999-02-04 | Unisearch Limited | Catalytic molecules |
| IL145034A0 (en) | 1999-03-05 | 2002-06-30 | Epigenesis Pharmaceuticals Inc | Method for validating/invalidating target(s) and pathways |
| AUPQ201499A0 (en) | 1999-08-04 | 1999-08-26 | Unisearch Limited | Treatment of inflammatory and malignant diseases |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| DE10346487A1 (de) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
| TWI322690B (en) * | 2006-05-11 | 2010-04-01 | Flysun Dev Co Ltd | Short interference ribonucleic acids for treating allergic dieases |
| DE102010007562A1 (de) * | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
| EP2708898A1 (de) | 2012-09-14 | 2014-03-19 | Sterna Biologicals GmbH & Co. Kg | Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten |
-
2015
- 2015-05-15 PL PL15001472T patent/PL3093022T3/pl unknown
- 2015-05-15 PT PT150014728T patent/PT3093022T/pt unknown
- 2015-05-15 DK DK15001472T patent/DK3093022T3/da active
- 2015-05-15 ES ES15001472T patent/ES2753436T3/es active Active
- 2015-05-15 EP EP15001472.8A patent/EP3093022B1/en active Active
- 2015-05-15 HU HUE15001472A patent/HUE046190T2/hu unknown
- 2015-05-15 SI SI201530949T patent/SI3093022T1/sl unknown
-
2016
- 2016-05-12 CA CA2985858A patent/CA2985858C/en active Active
- 2016-05-12 CN CN202210796084.9A patent/CN115137827A/zh active Pending
- 2016-05-12 KR KR1020177036013A patent/KR20180004816A/ko not_active Application Discontinuation
- 2016-05-12 WO PCT/EP2016/000782 patent/WO2016184556A1/en active Application Filing
- 2016-05-12 JP JP2018511332A patent/JP2018515611A/ja active Pending
- 2016-05-12 BR BR112017024394-6A patent/BR112017024394A2/pt not_active Application Discontinuation
- 2016-05-12 RU RU2017143014A patent/RU2720988C2/ru active
- 2016-05-12 US US15/574,345 patent/US10487325B2/en active Active
- 2016-05-12 CN CN201680027457.9A patent/CN107771082A/zh active Pending
- 2016-05-12 AU AU2016264772A patent/AU2016264772B2/en active Active
- 2016-05-12 NZ NZ736807A patent/NZ736807A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017143014A3 (da) | 2019-10-25 |
| RU2017143014A (ru) | 2019-06-17 |
| PL3093022T3 (pl) | 2020-02-28 |
| US20190062737A1 (en) | 2019-02-28 |
| WO2016184556A1 (en) | 2016-11-24 |
| BR112017024394A2 (pt) | 2018-07-24 |
| CA2985858C (en) | 2023-10-10 |
| EP3093022A1 (en) | 2016-11-16 |
| CN115137827A (zh) | 2022-10-04 |
| NZ736807A (en) | 2024-08-30 |
| KR20180004816A (ko) | 2018-01-12 |
| EP3093022B1 (en) | 2019-08-07 |
| AU2016264772B2 (en) | 2021-09-09 |
| US10487325B2 (en) | 2019-11-26 |
| AU2016264772A1 (en) | 2017-11-16 |
| CN107771082A (zh) | 2018-03-06 |
| HUE046190T2 (hu) | 2020-02-28 |
| SI3093022T1 (sl) | 2019-12-31 |
| PT3093022T (pt) | 2019-11-11 |
| ES2753436T3 (es) | 2020-04-08 |
| CA2985858A1 (en) | 2016-11-24 |
| RU2720988C2 (ru) | 2020-05-15 |
| JP2018515611A (ja) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002736A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3145493T3 (da) | Fremgangsmåder og sammensætninger vedrørende exosomer | |
| DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
| BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3230318T3 (da) | Immune checkpoint-inhibitor-kombinationer | |
| DK3093022T3 (da) | Gata-3-inhibitorer til anvendelse i behandlingen af th2-drevet astma | |
| DK3132009T3 (da) | Fremgangsmåde | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3212776T3 (da) | Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| DK3159296T3 (da) | Reb til elevator og fremstillingsfremgangsmåde dertil | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| MA41266A (fr) | Cataplasme | |
| DK3180335T3 (da) | Cytokrom-p450-inhibitorer og anvendelser deraf | |
| DK3586840T3 (da) | Mmp7-hæmmere til anvendelse i behandling af cystitis | |
| ITUB20156002A1 (it) | Composizione e metodo per trattare i nematodi | |
| DK3155422T3 (da) | Demaskering af endotoxiner i opløsning | |
| DK3102209T3 (da) | Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet | |
| DK3359183T3 (da) | Polyepitop-konstrukter til anvendelse i immunoterapy |